Avanclia (Rosiqlitazone)

Phase 2Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

Avanclia (Rosiqlitazone) is one of 13 small molecule programs targeting Glucose intolerance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glucose IntoleranceActive, not recruiting

Glucose IntolerancePhase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Glucose Intolerance

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Januvia

ZZydus Therapeutics Inc.

Rayos

Aldactone

1 5

Avandia

Alnylam Pharmaceuticals

Phase 3

1 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Trulicity

Eli Lilly

Phase 2

1 8

Mifeprex

DDanco

Phase 2

1 9

Glucophage

EMD Serono

Phase 1

1 10

Avandia

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glucose intolerance1 trial

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00064727·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Avanclia (Rosiqlitazone). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avanclia (Rosiqlitazone) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avanclia (Rosiqlitazone). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Avanclia (Rosiqlitazone)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glucose intolerance1 trial

References

Drug Info

Quick Facts

Related News